Altamira Therapeutics to Sell Majority Stake in Bentrio Unit

By Dean Seal

Altamira Therapeutics has agreed to sell a 51% stake in its subsidiary Altamira Medica AG, which produces the allergy spray Bentrio, to a Swiss private equity investor.

The biopharmaceutical company said Friday that the sale is part of its strategic repositioning around RNA delivery technology.

Altamira…